Dan T. Vogl

17.9k total citations · 1 hit paper
125 papers, 4.0k citations indexed

About

Dan T. Vogl is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Dan T. Vogl has authored 125 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hematology, 60 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Dan T. Vogl's work include Multiple Myeloma Research and Treatments (77 papers), Protein Degradation and Inhibitors (23 papers) and Cancer Treatment and Pharmacology (20 papers). Dan T. Vogl is often cited by papers focused on Multiple Myeloma Research and Treatments (77 papers), Protein Degradation and Inhibitors (23 papers) and Cancer Treatment and Pharmacology (20 papers). Dan T. Vogl collaborates with scholars based in United States, France and Canada. Dan T. Vogl's co-authors include Edward A. Stadtmauer, Adam D. Cohen, Alfred L. Garfall, Brendan M. Weiss, Wei‐Ting Hwang, William H. Redd, Meredith Smith, Carl H. June, Bruce L. Levine and J. Joseph Melenhorst and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dan T. Vogl

118 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Dan T. Vogl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dan T. Vogl United States	30	1.9k	1.8k	1.5k	638	469	125	4.0k
Simon J. Harrison Australia	38	2.8k 1.4×	2.5k 1.4×	2.5k 1.6×	855 1.3×	416 0.9×	246	5.6k
R. M. Fox Australia	29	957 0.5×	2.1k 1.2×	1.4k 0.9×	477 0.7×	379 0.8×	77	4.8k
Sung‐Soo Yoon South Korea	35	1.6k 0.8×	1.5k 0.8×	1.8k 1.2×	630 1.0×	233 0.5×	342	4.2k
Bridget A. Robinson New Zealand	37	1.3k 0.7×	2.0k 1.1×	281 0.2×	439 0.7×	400 0.9×	140	4.4k
Gerard M.J. Bos Netherlands	34	698 0.4×	908 0.5×	1.5k 0.9×	1.2k 1.9×	162 0.3×	134	4.7k
Victor M. Santana United States	43	2.0k 1.0×	2.0k 1.1×	643 0.4×	311 0.5×	396 0.8×	148	5.4k
Josef S. Smolen Austria	24	1.7k 0.9×	850 0.5×	966 0.6×	1.2k 1.8×	302 0.6×	37	5.3k
Maria Gavriatopoulou Greece	37	2.2k 1.2×	2.0k 1.1×	2.5k 1.6×	465 0.7×	294 0.6×	376	5.5k
Howard Ozer United States	38	899 0.5×	2.6k 1.4×	1.2k 0.8×	1.1k 1.7×	364 0.8×	143	5.5k
Sikander Ailawadhi United States	28	1.1k 0.6×	1.4k 0.8×	1.7k 1.1×	301 0.5×	181 0.4×	312	3.1k

Countries citing papers authored by Dan T. Vogl

Since Specialization

Citations

This map shows the geographic impact of Dan T. Vogl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan T. Vogl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan T. Vogl more than expected).

Fields of papers citing papers by Dan T. Vogl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan T. Vogl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan T. Vogl. The network helps show where Dan T. Vogl may publish in the future.

Co-authorship network of co-authors of Dan T. Vogl

This figure shows the co-authorship network connecting the top 25 collaborators of Dan T. Vogl. A scholar is included among the top collaborators of Dan T. Vogl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan T. Vogl. Dan T. Vogl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hubbeling, Harper, Kang Yu, Michael J. LaRiviere, et al.. (2025). Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma. Blood Advances. 10(4). 1395–1399.

Gaballa, Mahmoud, Omar Castañeda Puglianini, Adam D. Cohen, et al.. (2024). BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.. Journal of Clinical Oncology. 42(16_suppl). 7519–7519. 1 indexed citations

Sussman, Jonathan, Alfred L. Garfall, Adam D. Cohen, et al.. (2024). Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation. 60(1). 64–68. 2 indexed citations

Bar, Noffar, Andrew J. Yee, Binod Dhakal, et al.. (2024). P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series. Clinical Lymphoma Myeloma & Leukemia. 24. S44–S45. 1 indexed citations

Stalker, Margaret, Alfred L. Garfall, Dan T. Vogl, et al.. (2024). Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. European Journal Of Haematology. 114(3). 443–447. 3 indexed citations

Tang, Yan, Wei Liu, Omar Johnson, et al.. (2023). Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. Blood. 143(2). 139–151. 9 indexed citations

Lin, Cindy, Laura Garcia-Gerique, Jérôme Mastio, et al.. (2023). S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. Cancer Research Communications. 3(3). 420–430. 9 indexed citations

Djulbegovic, Mia, Meredith Doherty, Kan Chen, et al.. (2023). A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma. Blood. 142(Supplement 1). 909–909. 2 indexed citations

Deng, Hui, Cindy Lin, Laura Garcia-Gerique, et al.. (2022). A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Research. 82(19). 3561–3572. 59 indexed citations

10.

Lin, Cindy, Hui Deng, Joann Strnad, et al.. (2020). A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Molecular Cancer Therapeutics. 19(7). 1530–1538. 118 indexed citations

11.

Vogl, Dan T., Jonathan L. Kaufman, Omar Nadeem, et al.. (2020). TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 37–38. 17 indexed citations

12.

Cohen, Jordana B., Matthew B. Palmer, Sidney Kobrin, et al.. (2018). A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney International. 94(1). 199–205. 85 indexed citations

13.

Huntington, Scott F., Brendan M. Weiss, Dan T. Vogl, et al.. (2015). Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. The Lancet Haematology. 2(10). e408–e416. 165 indexed citations

14.

Vij, Ravi, Shaji Kumar, Mei-Jie Zhang, et al.. (2014). Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 21(2). 335–341. 42 indexed citations

15.

Dolloff, Nathan G., Joshua E. Allen, David T. Dicker, et al.. (2012). Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. Molecular Cancer Therapeutics. 11(11). 2321–2330. 12 indexed citations

16.

Nazha, Aziz, Richard J. Cook, Dan T. Vogl, et al.. (2010). Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplantation. 46(1). 59–63. 24 indexed citations

17.

Vogl, Dan T., Edward A. Stadtmauer, Paul G. Richardson, et al.. (2009). Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology. 147(4). 531–534. 25 indexed citations

18.

Tsai, Donald E., Selina M. Luger, Charalambos Andreadis, et al.. (2008). A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5619–5625. 29 indexed citations

19.

Olin, Rebecca L., Kim E. Nichols, Mojdeh Naghashpour, et al.. (2008). Successful use of the anti‐CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. American Journal of Hematology. 83(9). 747–749. 57 indexed citations

20.

DiNardo, Courtney D., Bonnie Ky, Dan T. Vogl, et al.. (2008). Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Medical Oncology. 25(3). 299–302. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact